These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 8614567)

  • 1. Selegiline protects dopaminergic neurons in culture from toxic factor(s) present in the cerebrospinal fluid of patients with Parkinson's disease.
    Hao R; Ebadi M; Pfeiffer RF
    Neurosci Lett; 1995 Nov; 200(2):77-80. PubMed ID: 8614567
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The multiple actions of selegiline.
    Ebadi M; Sharma S; Shavali S; Sangchot P; Brekke L
    Proc West Pharmacol Soc; 2002; 45():39-41. PubMed ID: 12434521
    [No Abstract]   [Full Text] [Related]  

  • 3. Neuroprotective actions of selegiline.
    Ebadi M; Sharma S; Shavali S; El Refaey H
    J Neurosci Res; 2002 Feb; 67(3):285-9. PubMed ID: 11813232
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Selegiline normalizes, while l-DOPA sustains the increased number of dopamine neurons in the olfactory bulb in a 6-OHDA mouse model of Parkinson's disease.
    Chiu WH; Carlsson T; Depboylu C; Höglinger GU; Oertel WH; Ries V
    Neuropharmacology; 2014 Apr; 79():212-21. PubMed ID: 24291466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. L-deprenyl protects mesencephalic dopamine neurons from glutamate receptor-mediated toxicity in vitro.
    Mytilineou C; Radcliffe P; Leonardi EK; Werner P; Olanow CW
    J Neurochem; 1997 Jan; 68(1):33-9. PubMed ID: 8978707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoamine oxidase-inhibition and MPTP-induced neurotoxicity in the non-human primate: comparison of rasagiline (TVP 1012) with selegiline.
    Kupsch A; Sautter J; Götz ME; Breithaupt W; Schwarz J; Youdim MB; Riederer P; Gerlach M; Oertel WH
    J Neural Transm (Vienna); 2001; 108(8-9):985-1009. PubMed ID: 11716151
    [TBL] [Abstract][Full Text] [Related]  

  • 7. L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitro.
    Mytilineou C; Radcliffe PM; Olanow CW
    J Neurochem; 1997 Jan; 68(1):434-6. PubMed ID: 8978757
    [TBL] [Abstract][Full Text] [Related]  

  • 8. L-deprenyl (selegiline) limits the repetitive firing of action potentials in rat hippocampal CA1 neurons via a dopaminergic mechanism.
    Huang CC; Tsai JJ; Hsu KS
    Brain Res; 1997 Apr; 753(1):27-35. PubMed ID: 9125428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trophic effects of selegiline on cultured dopaminergic neurons.
    Kontkanen O; Castrén E
    Brain Res; 1999 May; 829(1-2):190-2. PubMed ID: 10350547
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comprehensive review of rasagiline, a second-generation monoamine oxidase inhibitor, for the treatment of Parkinson's disease.
    Chen JJ; Swope DM; Dashtipour K
    Clin Ther; 2007 Sep; 29(9):1825-49. PubMed ID: 18035186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The neuroprotective and neuronal rescue effects of (-)-deprenyl.
    Magyar K; Szende B; Lengyel J; Tarczali J; Szatmáry I
    J Neural Transm Suppl; 1998; 52():109-23. PubMed ID: 9564614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neuroprotective Effects and Mechanisms of Action of Multifunctional Agents Targeting Free Radicals, Monoamine Oxidase B and Cholinesterase in Parkinson's Disease Model.
    Liu Z; Cai W; Lang M; Yan R; Li Z; Zhang G; Yu P; Wang Y; Sun Y; Zhang Z
    J Mol Neurosci; 2017 Apr; 61(4):498-510. PubMed ID: 28144826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor.
    Finberg JP; Takeshima T; Johnston JM; Commissiong JW
    Neuroreport; 1998 Mar; 9(4):703-7. PubMed ID: 9559942
    [TBL] [Abstract][Full Text] [Related]  

  • 14. L-deprenyl fails to protect mesencephalic dopamine neurons and PC12 cells from the neurotoxic effect of 1-methyl-4-phenylpyridinium ion.
    Vaglini F; Pardini C; Cavalletti M; Maggio R; Corsini GU
    Brain Res; 1996 Nov; 741(1-2):68-74. PubMed ID: 9001706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cerebrospinal fluid of Parkinson's disease patients inhibits the growth and function of dopaminergic neurons in culture.
    Hao R; Norgren RB; Lau YS; Pfeiffer RF
    Neurology; 1995 Jan; 45(1):138-42. PubMed ID: 7824104
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modification of levodopa responses by deprenyl (selegiline): an electrophysiological and behavioral study in the rat relevant to Parkinson's disease.
    Mercuri NB; Scarponi M; Federici M; Bonci A; Siniscalchi A; Bernardi G
    Ann Neurol; 1998 May; 43(5):613-7. PubMed ID: 9585355
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroprotection of MAO-B inhibitor and dopamine agonist in Parkinson disease.
    Kong P; Zhang B; Lei P; Kong X; Zhang S; Li D; Zhang Y
    Int J Clin Exp Med; 2015; 8(1):431-9. PubMed ID: 25785014
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic and proteomic study to survey the mechanism of action of the anti-Parkinson's disease drug, rasagiline compared with selegiline, in the rat midbrain.
    Weinreb O; Amit T; Sagi Y; Drigues N; Youdim MB
    J Neural Transm (Vienna); 2009 Nov; 116(11):1457-72. PubMed ID: 19396396
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The neuronal survival effects of rasagiline and deprenyl on fetal human and rat ventral mesencephalic neurones in culture.
    Goggi J; Theofilopoulos S; Riaz SS; Jauniaux E; Stern GM; Bradford HF
    Neuroreport; 2000 Dec; 11(18):3937-41. PubMed ID: 11192605
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selegiline enhances NGF synthesis and protects central nervous system neurons from excitotoxic and ischemic damage.
    Semkova I; Wolz P; Schilling M; Krieglstein J
    Eur J Pharmacol; 1996 Nov; 315(1):19-30. PubMed ID: 8960860
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.